NeuroBo Pharmaceuticals, Inc. (NRBO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Hyung-Heon Kim | CEO, President & Director | 625.16k | -- | 1975 |
| Mr. Marshall H. Woodworth | Chief Financial Officer | 154.5k | -- | 1958 |
| Dr. Mi-Kyung Kim | Chief Scientific Officer | -- | -- | -- |
| Mr. Robert Homolka | Senior Vice President of Clinical Operations | -- | -- | -- |
NeuroBo Pharmaceuticals, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 8
Description
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
November 7, 2024 at 1:01 PM UTC
NeuroBo Pharmaceuticals, Inc. Earnings Date